NCT03978780
Erector Spinae Block vs. Placebo Block Study
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 16 versions: 15 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Stopped Trial status changed: Not Yet Recruiting → Terminated Sponsor's reason: The study team has decided not to proceed with this study idea, as it is already established as standard practice at Women's College Hospital and therefore does not meet criteria for evaluation as a research study. Show 5 more changesShow less
- Eligibility criteria expanded, about 18 words
- Primary completion date changed from estimate of Jun 2027 to Apr 30, 2026
- Start date changed from estimate of Jun 2026 to Apr 30, 2026
- Secondary endpoints: details revised at 2 of 7 entries
- Site details revised
- Notable Primary completion date: Jun 2026 to Jun 2027
- Start date: Jun 2025 to Jun 2026
- Study completion date: Jan 2027 to Jan 2028
- Notable Primary completion date: Sep 2025 to Jun 2026
- Start date: Sep 2024 to Jun 2025
- Study completion date: Jan 2026 to Jan 2027
- Notable Primary completion date: Sep 2024 to Sep 2025
- Start date: Sep 2023 to Sep 2024
- Study completion date: Dec 2024 to Jan 2026
- Notable Primary completion date: May 2023 to Sep 2024
- Start date: Sep 2022 to Sep 2023
- Study completion date: Aug 2023 to Dec 2024
Show 9 earlier versionsHide 9 earlier versions
- Notable Start date: Jan 2022 to Sep 2022v11
- Notable Start date: Sep 15, 2021 to Jan 2022
- Eligibility criteria expanded, about 6 words
- Notable Start date: May 3, 2021 to Sep 15, 2021v8
Notable Primary completion date: Jan 2022 to May 2023v7 Show 9 more changesShow less
- Start date: Jan 2021 to May 3, 2021
- Eligibility criteria shortened, about 7 words
- Primary endpoints: 1 to 2
- Enrollment target: 70 to 60
- Study completion date: Aug 2022 to Aug 2023
- Interventions: Erector spinae plane block (Procedure), Ropivacaine with Epinephrine (Drug), Serratus Block (Procedure) to Erector spinae plane block (Procedure), Placebo Block (Procedure)
- Secondary endpoints: 9 to 7
- Study description expanded, about 188 words
- Study title shortened, about 5 words
- Minor Interventions: Erector spinae plane block (Procedure), Serratus Block (Procedure) to Erector spinae plane block (Procedure), Ropivacaine with Epinephrine (Drug), Serratus Block (Procedure)v6
- Notable Eligibility criteria expanded, about 4 words
- Secondary endpoints: 8 to 9
- Notable Start date: Jun 2020 to Jan 2021
- Primary completion date: Jun 2022 to Jan 2022
- Notable Enrollment target: 130 to 70
- Eligibility criteria shortened, about 3 words
- Study sites: 0 to 1
- Notable Start date: Dec 2019 to Jun 2020
- Primary completion date: Dec 2021 to Jun 2022
- Study completion date: Feb 2022 to Aug 2022
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (7)
Show 2 moreShow less
Arms and interventions
Patients randomised to the Control group will then receive a sham subcutaneous injection of 0.5ml normal saline injected at the same site as the ESP block (see above) under ultrasound guidance to stimulate a real block procedure.
Local anaesthetic infiltration utilising 1% lidocaine will occur, and an 80mm 22G block needle will be inserted using an in-plane cranial to caudad approach, the needle will be advanced to target the interfascial plane deep to the erector spinae muscle at the T2 transverse process. Once the needle tip is in the correct position, 20 ml of the local anaesthetic (ropivacaine 0.5% with 1:400,000 epinephrine) will be administered slowly in 5 ml aliquots under frequent aspiration and correct spread in the interfascial plane will be observed.
Procedures: Erector spinae plane block, Placebo Block
Sites
1 site in 1 country
- Women's College HospitalToronto, Ontario, Canada